Clinical trial
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced…
NCT00498407 · Clavis Pharma, Industry · Completed
Key facts
| NCT number | NCT00498407 |
|---|---|
| Title | A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer |
| Official title | A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer |
| Lead sponsor | Clavis Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Colorectal Cancer, Colorectal Cancer |
| Intervention type | Drug |
| Interventions | CP-4055 |
| Enrollment | 16 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jul 10, 2007 |
| Last update posted | Jun 4, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: